Advertisement ERYTECH Pharma wins US patent for erythrocytes containing arginine deiminase - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ERYTECH Pharma wins US patent for erythrocytes containing arginine deiminase

ERYTECH Pharma announced the issuance of a new patent in the US.

A United States patent entitled "Erythrocytes Containing Arginine Deiminase" has been issued by the U.S. Patent and Trademark Office (USPTO) as U.S. Patent No. 9,125,876. It covers the use of ERY-ADI, a tumor starvation product candidate arising from ERYTECH’s encapsulation platform.

The patent received 363 days of patent term adjustment (PTA), and with that PTA, has a term in the United States through at least April 2027. The term of this patent may also be eligible for limited patent term extension in the United States under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The counterparts of this patent have already been issued in Europe, China, Japan, Canada, Korea and Australia.

ERYTECH’s patent portfolio consists of 12 patent families covering its technology platform and applications in and outside oncology and a license from the U.S. National Institutes of Health covering a diagnostic method to predict the efficacy of L-asparaginase.

About ERY-ADI

ERY-ADI, arginine deiminase encapsulated in red blood cells, is one of two new tumor starvation product candidates arising from ERYTECH’s encapsulation platform. In addition to L-asparaginase, the active ingredient in our lead product candidate ERY-ASP, we are leveraging our proprietary ERYCAPS technology to develop additional product candidates, encapsulating other therapeutic drug substances.

Based on our preclinical research, we have identified two other tumor starvation enzymes, methionine-?-liase (MGL) and arginine deiminase (ADI), which we believe can benefit from being encapsulated in red blood cells. MGL and ADI degrade methionine and arginine respectively, two amino acids that are essential for tumor cells to survive and grow.

The resulting product candidates, ERY-MET and ERY-ADI, are currently in preclinical development. We expect to commence a Phase 1 clinical trial with ERY-MET in 2016 and a Phase 1 clinical trial with ERY-ADI as early as 2017.